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ABSTRACT
The present study was undertaken to investigate the effects of the T-type calcium channel
blocker, Mibefradil, on white adipocytes. Unexpected for a T-type channel blocker, Mibefradil
was found to increase intracellular calcium levels, cause lipid droplet fusion, and result in cell
death. Calcium imaging of white adipocytes showed an increase of calcium concentration by
Mibefradil at concentrations ranging from10-50 µM. The elevation in calcium by Mibefradil was
significantly reduced by pretreatment of cells with Thapsigargin, an endoplasmic reticulum (ER)
specific Ca ATPase inhibitor. Additionally, lipid droplet fusion and cell death were also
attenuated by Thapsigargin pretreatment in white adipocytes. We conclude that Mibefradil
elevated intracellular calcium levels, induced lipid droplet fusion and cell death in white

adipocytes via mobilizing intracellular calcium stores from the ER. These results describe novel
effects of Mibefradil on white adipocytes and may provide new insight into how this drug might
be repurposed in obesity research.
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METHODS

Cell Culture
All cells were maintained at 37 °C in a 5% CO2 incubator. White preadipocytes were kindly
provided by Dr. Bingzhong Xue’s Lab. To differentiate mature adipocytes, we plated preadipocytes with pre-adipocyte medium [Dulbecco’s Modified Eagle Medium (DMEM), 1:1 (v/v)
containing 10% fetal calf serum, 15mmol/L 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
(HEPES), and antibiotics]. Cells were grown into 90% confluence in growth medium and were
then induced to differentiate with a differentiation medium [DMEM, 1:1 (v/v) containing 10%
fetal bovine serum, 15mM HEPES, 33µM biotin, 17 µM pantothenate, 100nM insulin, 1 µM
dexamethasone, 0.25 mM isobutyl methylxanthine (IBMX), 1 µM BRL49653, 100 U/ml
penicillin, and 100 µg/ml streptomycin]. After two days in differentiation cocktail, cells were
changed to and maintained in adipocyte medium [ DMEM/Ham’s F-10, 1:1 (v/v), 0.2% FBS, 15
Mm HEPES, 33 µM biotin, 17 µM pantothenate, 100 U/ml penicillin, and 100 µg/ml
streptomycin]. At day 6, all the cells were differentiated.
Image acquisition and analysis
Petri dishes containing white adipocytes were placed on a fixed stage that was centered below
the objective of an upright microscope (BS51W1F, Olympus, Japan). The upright microscope
was mounted on a manual translation stage (Siskiyou, San Francisco, CA). Phase contrast and
fluorescent images of white adipocytes were captured before (-5 and 0 min) and at defined times
after Mibefradil application. If pharmacological inhibitors were used in combination with
Mibefradil application, the inhibitor was directly applied to the dish for the desired amount of
time at the defined 5 min or 5 min 30 sec time marker. In the figures, changes in calcium
concentration were expressed as a percent change comparing concentrations just before drug
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addition and peak calcium levels after drug addition. In all experiments, the first calcium peak
was used for analysis, because this was demonstrated to be the direct result of drug action. For
cells in which the calcium concentration did not return to baseline calcium levels and that
showed a continued increase in calcium level it was difficult to identify the first peak. In such
cases, the time point at which all other cells showed their first peak after treatment was
designated as the first peak value for a cell. Statistical analysis was performed with the software
ORIGIN DATA ANALYSIS AND GRAPHING software (OriginLab, Northampton, MA)
Significance between conditions was determined by using either a Student’s t-test and ANOVA.
All data were expressed as mean ± SEM.
Ca2+ imaging
Cells were loaded with 1mM fura-2 AM (Molecular Probes, Eugene, OR, USA) in DMSO and
allowed to sit for 30 min to give the dye time to diffuse. Care was taken to load cells just enough
to yield sufficient fluorescence and avoid overloading with Fura-2. Cells were washed 3x with
extracellular medium (refer to pharmacological agents) then allowed to sit for 20 min for
desertification. Acquisition and analysis of calcium images were conducted using Live
Acquisition and Offline Analysis software (Till Photonics, FEI, Germany). Images were acquired
using 340 nm and 380 nm excitation wavelengths with 100ms exposure time at 5% light
intensity every 30 sec. The I cytosolic calcium concentration within an adipocyte was determined
by placing a box into the cytosol area of each adipocyte and by calculating the ratio of emission
signals at 340 and 380 nm after background subtraction. This ratio was used as a measure of
underlying changes in intracellular calcium concentration. No actual calcium concentrations can
be reported, because the fluorescence values were not calibrated on the imaging system.
Adipocytes were excluded from analysis if their pretreatment ratios exceeded a ratio of 1, which
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indicated a calcium concentration above normal resting values, as established in earlier
experiments on the system.
Pharmacological Agents
Extracellular medium: 152 mM NaCl, 2.8 mM KCL, 10 mM HEPES, 2 mM Calcium Chloride,
10 mM of glucose. Zero calcium extracellular medium: Same ingredients as extracellular
medium excluding calcium chloride and addition of 5 mM EGTA. FCCP (Tocris) and Mibefradil
(Tocris) were dissolved in DMSO. Final dilutions of DMSO in solutions were less than 1:1000.
FCCP was dissolved in 72 µl of DMSO to make a stock solution of 5 mM. Mibefradil was
dissolved in 172 µl of DMSO to make a stock solution 100 mM.

4

2

INTRODUCTION

Obesity refers to a condition where excess fat accumulates on a person’s body posing various
health risks to the individual. The word ‘obesity’ is sometimes used synonymously with the word
‘adiposity,’ which refers to morbid or severe overweight. Obesity alters the endocrine and
metabolic functions of white adipose tissue and increases the release of proinflammatory
molecules, hormones, and fatty acids. In principle, the white adipose tissue functions as an
energy reserve or active organ that employs different mechanisms to influence energy
homeostasis (Bambace et al., 2013). Adiposity has been described as the part of body mass that
comprises neutral lipids stored in the adipose tissue (Weisberg et al., (2003). It correlates closely
with vital physiological parameters like leptin concentrations, insulin sensitivity, and blood
pressure. Weisberg et al. (2003) reported the existence of positive correlations between adiposity
and obesity-related disorders, especially glucose intolerance, dyslipidemia, and hypertension.
However, the authors noted that visceral fat mass shows a closer correlation with obesity-related
pathology than the overall adiposity.
Adipose tissue plays a vital role in the lives of mammals because it serves as the primary source
of free fatty acids (FFA) during postprandial fasting for heat production and energy use
(Balistreri et al., 2010). Typically, mammals have two forms of adipose tissue: brown and white
tissues (Gesta et al., 2007). The two types of adipose tissue have different functions, as well as
different cellular localization and composition. White adipose tissue (WAT) is the major
constituent of the adipose tissue and provides the largest proportion of body fat and FFA. In
principle, WAT is distributed in various anatomic sites of the body with its primary depots being
intra-abdominal areas, peri-renal and intestinal sites, and subcutaneous areas of the abdomen,
thighs, and buttocks (Gesta et al., 2007). According to Wozniak et al. (2009), WAT appears to be

5

associated with two principal functions. First, it helps to control metabolism through insulin
sensitivity, adipocyte differentiation, and energy homeostasis. Secondly, it influences
inflammation through control mechanisms mediated by various anti-inflammatory molecules, as
well as activated immune and anti-inflammatory pathways (Balistreri et al., 2010). Although
each WAT subgroup has a specialized role, the excessive accumulation of WAT at any site of
the body influences the occurrence of obesity, as well as obesity-related illnesses. The most
common WAT excess occurs around the waist resulting in central obesity or ‘android obesity,’
which intensifies the risk of certain inflammatory pathologies (Balistreri et al., 2010). WAT
excess may also occur in lower parts of the body causing the development of ‘gynoid obesity,’
which lacks metabolic complications (Gesta et al., 2007).
Several hypotheses have been developed to shed light on the distribution of WAT and its
relationship with inflammatory and metabolic complications. Among the different theories, two
principal hypotheses have been given considerable attention. The first theory concentrates on
central obesity’s anatomy and its potential to drain inflammatory mediators and FFA into portal
circulation. In turn, the drained mediators and FFA act on the liver preferentially and affect
metabolic reactions significantly (Gesta et al., 2007). The second hypothesis considers the role of
different WAT cell properties in the development of inflammatory and metabolic diseases. Gesta
et al. (2006) detected key differences in gene expression between different WAT deposits in both
humans and rodents. Interestingly, other researchers have also observed a distinct mediator
profile between peripheral and visceral WAT, which seems to elucidate the link that exists
between metabolic complications and central obesity (Balistreri et al., 2010). The mediator
profile offers additional evidence for the heterogeneity of the cells of WAT (Gesta et al., 2007).
Also, WAT comprises fully-developed adipocytes and cell types such as macrophages,
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endothelial cells, fibroblasts, and preadipocytes, which are categorized as the stroma vascular
fractions (Cancello and Clement, 2006; Subramanian and Ferrante Jr., 2009). The macrophages,
preadipocytes, and adipocytes have inflammatory and metabolic functions that allow the WAT to
release mediators with varying biological effects (Fantuzzi, 2008; Lago et al., 2009). In
particular, macrophages influence the circulating level of different inflammatory molecules and
determine low-grade obesity-associated inflammation (Zeyda and Stulnig, 2007).
In the mammalian body, energy is preserved in lipid droplets as triacylglycerols. Recently,
researchers have made significant breakthroughs in promoting the understanding of lipid
droplets’ biology (Walther and Farese Jr., 2012; Brasaemle and Wolins, 2012). In particular,
microscopic observation has been identified as one of the most effective approaches to the
visualization of the striking capacity of the white adipocyte lipid droplets (LDs) to store lipids
(Konige et al., 2014). The majority of mature adipocytes contain a single lipid droplet within the
size range of 25 to about 150 μm in diameter (Konige et al., 2014). The droplet occupies the
largest cell volume and, thus, determines the size of the adipocyte. Also, adipose depots have
been known to enlarge through the mechanisms of hyperplasia and hypertrophy, which require
extensive and coordinated cellular and structural alterations to accommodate the growth and
emergence of the LD. Different studies have demonstrated that LDs control the capacity and
efficiency of adipocytes to carry out the esterification of fatty acids to form triglyceride and,
hence, protect the triglyceride stores inside the cells (Puri et al., 2008). The proteins surrounding
LDs comprise the ‘PAT’ proteins perilipin ADRP and TIP47 that target LDs and regulate the
biogenesis 11and size of such organelles (Puri et al., 2008). Investigators have further described
Cidec/FSP27 as a unique protein associated with lipid droplets, which negatively controls
lipolysis and enhances triglyceride accumulation in adipocytes (Puri et al., 2008). Cidec/FSP27
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has been classified as a CIDE-N type of domain-containing proteins in the protein family of
CIDE, which includes three protein members found in mice: FSP27; Cideb; and Cide (Puri et al.,
2008). The CIDE family also includes four human proteins: CIDEC; CIDEB; and CIDEA.
Notably, the proteins have a typical C-terminal containing CIDE-C domain and an N-terminal
with a CIDE-N domain. In addition, the proteins have an important homology occurring between
CIDE-N domains of the CIDE proteins and regulatory domains associated with apoptotic factors
of DNA fragmentation, DFF45 (a DFF40 inhibitor) and DFF40 (nuclease activated by caspase)
(Puri et al., 2008). Researchers also found that Cidec/FSP27 acts as an LD-related protein in the
adipocytes of mice to control fat deposition. Moreover, Cidea has been known to show high
expression in adipose tissues. In mice, the protein is primarily restricted to the brown adipose
tissue but highly expressed in the human WAT. Puri et al. (2008) found substantial evidence
supporting the view that Cidea localizes to LDs and controls the deposition of triglyceride in
various cell types, including adipocytes. Remarkably, the researchers discovered that the
expression of both Cidec/FSP27 and Cidea in the WAT of overweight human subjects shows a
positive correlation with insulin sensitivity in the body, as well as the LD protein perilipin. Thus,
obesity has been identified as one of the primary causes of diabetes.
The magnitude and prevalence of obesity, especially in adolescents, is on the rise. Apart from
environmental and genetic factors, the intake of calcium has been described as a key dietary
component that shows an inverse relationship with obesity and body mass index (Burbano et al.,
2016). Recently, apoptosis modulation in the adipose tissue has emerged as a promising strategy
against obesity because the elimination of adipocytes is expected to reduce body fat significantly.
Studies have shown that Ca2+ signaling induces apoptosis in the adipocytes (Parikh and
Yanovski, 2003). Therefore, intracellular calcium has a critical function in the metabolic
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derangements linked to obesity. Shi et al. (2000) pointed out that increasing intracellular calcium
by stimulating voltage-mediated or receptor calcium channels stimulates the activity and
expression of the fatty acid synthase (FAS). FAS is crucial to the commencement of lipogenesis
and inhibits both agonist-stimulated lipid breakdown and basal lipolysis in adipocytes. Such
effects are often reversed through the antagonism of calcium channels (Shi et al., 2000).
Accordingly, increasing intracellular calcium seems to exert a coordinated regulation over
lipolysis and lipogenesis, which enhances the accumulation of triglyceride in adipocytes. As
such, an increase in intracellular calcium simultaneously stimulates lipogenesis and suppresses
lipolysis resulting in adipocyte hypertrophy and lipid filling. Past investigations have further
implicated Ca2+ in the regulation of adipogenesis, which is thought to promote obesity in humans
and rodents (Shi et al., 2000). For instance, increasing intracellular calcium, by inhibiting the
CaATPase or stimulating the influx of calcium ions has been known to suppress the initial stages
of adipocyte differentiation in murine (Shi et al., 2000). Thus, the effect of calcium signaling on
body fat reduction provides a powerful rationale for developing mechanistic approaches to the
study of calcium’s anti-obesity properties. Shi et al. (2000) reported that increasing intracellular
calcium in the early phases of differentiation resulted in the suppression of adipocyte
differentiation in humans, which matched previous observations about adipocyte differentiation
in murine. On the other hand, increasing intracellular calcium during the late phases of
differentiation enhanced human adipocyte differentiation (Shi et al., 2000). Therefore,
considerable evidence suggests that promoting Ca2+ signaling has a biphasic regulatory function
in the differentiation of human adipocytes. As a result, it inhibits the initial differentiation stages
while enhancing the final stages of lipid filling and differentiation (Shi et al., 2000). The role of
Ca2+ signaling in the differentiation of adipocytes not only elucidates the processes of energy
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homeostasis and adipogenesis but also establishes a critical target for the future development of
effective therapeutic interventions in obesity. Accordingly, Bagchi and Preuss (2012)
recommended the use of dietary calcium as an anti-obesity strategy. The authors demonstrated
that an increase in dietary calcium confers protection against obesity by reducing intracellular
calcium levels, which in turn decreases lipid storage in the adipocytes.
Our research on white adipocytes focused primarily on the presence of voltage gated calcium
channels and their functional roles. Several voltage gated calcium channel blockers were utilized
in our experiments. However, treatment of one such drug, Mibefradil, had the effect of
increasing calcium levels in white adipocytes. Typically, Mibefradil is categorized as a calcium
channel blocker because it affects calcium movements into the cells of blood vessels and the
heart. Consequently, the agent relaxes the blood vessels while increasing oxygen and blood
supply to the heart to minimize its workload. Additionally, Mibefradil functions as a tetraline
substituted with benzimidazole. Thus, it selectively inhibits and binds the T-type forms of
calcium channels. More specifically, Mibefradil acts as a tetralol-related calcium channel blocker
that prevents the movement of calcium across the low-voltage T calcium channels and the highvoltage L calcium channels in the vascular and cardiac smooth muscles (DrugBank, 2016).
However, the drug is relatively more selective for T-type channels. Usually, vascular smooth
muscles experience vasodilation, which decreases both blood pressure and peripheral resistance
in the vascular vessels. Thus, chronic dosing of the drug often increases cardiac output slightly
(DrugBank, 2016). Research has further demonstrated that Mibefradil slows the atrioventricular
node and sinus conduction, which leads to an increase in peripheral resistance and decrease in
the heart rate. In addition, the drug has been known to prolong the recovery time of the corrected
sinus node and lengthen AH interval while raising the Wenckebach point (DrugBank, 2016). The
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role of Mibefradil as a calcium channel blocker is essential to the antagonism of calcium
channels that reverses the effects of FAS (member of the death receptor family). In our study
with adipocytes, the calcium channel blocker Mibefradil had the unusual effect of raising
intracellular calcium levels. It also induced lipid droplet fusion and cell death. Since calcium
signaling has dual functions in the maintenance of homeostasis and the triggering of
adipogenesis and lipid droplets regulate the storage and release of triacylglycerols, investigating
the role of Mibefradil in calcium signaling, lipid droplet changes, and adipocyte apoptosis could
provide us with possible strategies to control and overcome obesity.
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RESULTS

Application of Mibefradil to white adipocytes results in an increase in intracellular calcium.
The first experiment was to test the effect of Mibefradil on intracellular calcium levels. White
adipocytes were loaded with Fura-2 (see Methods for details). We examined the effect of
Mibefradil on these Fura-2 loaded adipocytes using a microscopy system specialized for fast
calcium imaging (see Methods for details). Baseline values were acquired for 5 minutes prior to
the application of Mibefradil, and acquired 30 minutes after the addition of Mibefradil to a dish
containing Fura-2 loaded adipocytes. Mibefradil application resulted in an increase in
intracellular calcium, which was evident by the increase in the fluorescence intensity ratio
following the Mibefradil treatment (Fig. 1A-E). In most cases, after the maximum peak had
been reached calcium levels declined close to baseline values seen prior to Mibefradil treatment
(Fig. 1). Responses in individual adipocytes were variable though, as shown in Fig. 1D, where
one cell upon 40 µM Mibefradil treatment responded with the characteristic rise and subsequent
fall of calcium levels, while the other cell showed calcium levels that continued to rise after
Mibefradil treatment.
Analyzing experiments of white adipocytes treated with 10 µM Mibefradil showed a significant
increase in calcium at P<0.001 (Fig 2). To determine dose-dependency of the drug, Mibefradil
concentrations of 10 µM, 25 µM, 30 µM, 40 µM, and 50 µM were each tested. Among the
varying concentrations of Mibefradil on average an increase in intracellular calcium levels was
seen about 3 min after addition (Fig. 1A-E). A 10 µM Mibefradil treatment resulted in an
increase in intracellular calcium levels that reached an average maximum of 0.86± 0.09. 25 µM,
30 µM, 40 µM, and 50 µM Mibefradil treatment resulted in increases in intracellular calcium
levels that reached maximum values of 0.96 ± 0.06, 1.13 ± 0.19, 1.07 ± 0.06, and 1.25 ± 0.1,
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respectively. Each of these concentrations induced a significant increase in calcium (P< 0.001).
A One Way ANOVA test concluded that there was no overall significant difference (P>0.05)
between treatments, suggesting that increasing concentrations of Mibefradil did not result in a
dose-dependent effect (Fig. 3).
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B.
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D.

15

E.
Figure 1 A-E. Representative examples of Mibefradil induced calcium increases in white
adipocytes. Fluorescent intensity ratiometric graphs showing the response of different
concentrations of Mibefradil. Arrow indicates time of Mibefradil application. Number of cells
denoted by N.

Figure 2. Mibefradil (10 µM) induced calcium increase in white adipocytes. Bar graph
illustrates percent change of calcium. Mibefradil (MIB) dissolved in DMSO. DMSO treatment
showed no significant increase in calcium levels (P>0.05). MIB treatment resulted in a
significant increase in calcium peak levels (P<0.001). Number of cells denoted by N.
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Figure 3. Different concentrations of Mibefradil induced calcium increases in white
adipocytes. Bar graph illustrates average peak of calcium levels. Mibefradil dissolved in DMSO.
There was no significant difference among the different concentrations of Mibefradil (ANOVA
P>0.05). Number of cells denoted by N.

Application of Mibefradil to white adipocytes in extracellular medium devoid of calcium.
In order to test whether the increase in intracellular calcium upon treatment with Mibefradil was
due to calcium influx into the cytoplasm, 10 µM Mibefradil was applied to adipocytes in an
extracellular medium with nominally zero calcium and containing the calcium chelator EGTA
(5mM). A 30 min treatment of white adipocytes with Mibefradil (10 µM) in a zero calcium
medium led to a significant (P<0.001) increase in intracellular calcium. The lack of extracellular
calcium did not interfere with Mibefradil’s effect of inducing a calcium increase in white
adipocytes (compare to the effect of Mibefradil in normal medium, Figs. 1A, 2), suggesting that
Mibefradil’s effect of raising the intracellular calcium concentration in adipocytes was not
through calcium influx from the extracellular space, but likely resulted by calcium release from
an intracellular source of calcium (Fig. 4). There was an apparent delay in the increase in
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calcium levels, as well as a slower rise to peak in zero calcium medium, indicating that
extracellular calcium might play an accessory role in producing a normal Mibefradil induced
calcium response.

A.

B.
Figure 4A-B. Mibefradil induced calcium increase in white adipocytes in a zero calcium
environment. A) Representative graph of fluorescence excitation ratio (340nm/380nm)
corresponding to intracellular calcium levels over a period of 30 min in white adipocytes treated
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with 10 µM Mibefradil (MIB) in a zero calcium medium. B) Bar graph illustrates percent change
of calcium levels. Mibefradil dissolved in DMSO. DMSO (5 min) and DMSO peak showed no
significant increase in calcium levels (P>0.05). Adipocytes treated with Mibefradil in a zero
calcium environment showed a significant increase in calcium levels (P < 0.001). Number of
cells denoted by N.

Mibefradil does not cause a cytosolic calcium increase via release from the mitochondria
Mitochondria are known calcium stores and we next examined the potential role of mitochondria
in mediating the effect of Mibefradil on adipocytes. To deplete mitochondria of calcium, white
adipocytes were pretreated with the oxidative phosphorylation uncoupler, FCCP. Addition of
FCCP (10 µM) resulted in a transient increase in intracellular calcium levels that reached an
average maximum value of 0.9 ± 0.05 and returned to pretreatment values within 30 min of
application (Fig. 5). The increase in calcium levels following treatment was significantly
different from controls (P<0.001). In order to test whether the effect of a rise in intracellular
calcium levels by Mibefradil was attributed to release from the mitochondria, Mibefradil (40
µM) was applied to adipocytes pretreated with FCCP.
Experiments with white adipocytes pretreated with FCCP followed by a treatment with
Mibefradil (40 µM) did not inhibit Mibefradil from inducing an increase in intracellular calcium
levels (Fig. 6A). Interestingly, calcium levels continued to rise in pretreated cells and did not
recover (Fig. 6A). This appeared to indicate that the uncoupling of mitochondria and the
depletion of mitochondrial stores made cells increasingly susceptible to the Mibefradil induced
calcium increase.
Decreasing the concentration of Mibefradil to 30 µM produced similar results (Fig 7).
Preincubation of 10 µM FCCP for 30 min did not block the effect of increasing intracellular
calcium levels normally seen when Mibefradil was applied onto white adipocytes. When
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comparing calcium levels before and after addition of Mibefradil in pretreated adipocytes with
FCCP there was a significant difference at P<0.001 (Fig. 6B & 7B). Calcium levels after
addition of Mibefradil did not return to pretreatment values and this result indicated that the
source of calcium mobilized by Mibefradil was not the mitochondria. Given the strong and
irreversible effect of 30µM Mibefradil on FCCP pre-treated adipocytes, future experiments
should evaluate the effects of lower concentrations of Mibefradil.

Figure 5. FCCP induced calcium increase in white adipocytes. A) Representative graph
of fluorescence excitation ratio (340nm/380nm) corresponding to intracellular calcium levels
over a period of 30 min in white adipocytes treated with 10 µM FCCP. Number of cells denoted
by N.
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A.

B.
Figure 6A-B. Pretreatment of FCCP (10 µM) did not block Mibefradil (40 µM MIB)
induced calcium increase in white adipocytes. A) Representative graph of fluorescence excitation
ratio (340nm/380nm) corresponding to intracellular calcium levels over time in pretreated white
adipocytes with 10 µM FCCP followed by 40 µM Mibefradil (MIB). B) Bar graph illustrates
percent change of calcium levels. FCCP and Mibefradil dissolved in DMSO. DMSO (5 min) and
DMSO (10min) showed no significant increase in calcium levels (P>0.05). Pre-FCCP (5 min)
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and FCCP peak (10 min) showed a significant increase in calcium levels (P < 0.001). DMSO
(35 min 30 sec) and DMSO (44 min) showed no significant increase in calcium levels (P>0.05).
Post-FCCP (35min 30 sec) and Post-MIB peak (44 min) showed a significant increase in
calcium levels (P < 0.001). The mitochondrial calcium store was depleted by treating cells for
30 min with a mitochondrial oxidative phosphorylation uncoupler, 10 µM FCCP. Number of cell
denoted by N.
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A.

B.
Figure 7A-B. Pretreatment of FCCP (10 µM) did not block Mibefradil (30 µM MIB)
induced calcium increase in white adipocytes. A) Representative graph of fluorescence excitation
ratio (340nm/380nm) corresponding to intracellular calcium levels over time in pretreated white
adipocytes with 10 µM FCCP followed by 30 µM Mibefradil (MIB). B) Bar graph illustrating
percent change of calcium levels. FCCP and Mibefradil dissolved in DMSO. DMSO (5 min) and
DMSO (8 min) showed no significant increase in calcium levels (P>0.05). Pre-FCCP (5 min)
and FCCP peak (8 min) showed a significant increase in calcium levels (P < 0.001). DMSO (35
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min 30 sec) and DMSO (1hr 5 min) showed no significant increase in calcium levels (P>0.05).
Post-FCCP (35 min 30 sec) and Post-MIB peak (1 hr 5 min) showed a significant increase in
calcium levels (P < 0.001). The mitochondrial calcium store was depleted by treating cells for
30 min with a mitochondrial oxidative phosphorylation uncoupler, 10 µM FCCP. Number of
cells denoted by N.

Mibefradil causes a cytosolic calcium increase via release from the endoplasmic reticulum
To test whether the endoplasmic reticulum was involved in the mechanism mediating the effects
of Mibefradil on calcium levels in white adipocytes, we employed an inhibitor of the calcium
ATPase pump in the ER, Thapsigargin. Thapsigargin (10 µM) application by itself induced a
calcium transient in adipocytes (Fig.8). Intracellular calcium levels reached a maximum of
1.07 ± 0.06 following Thapsigargin application and returned to pretreatment values within 30
minute of application. The increase in calcium levels following treatment was significant
(P<0.001). We tested next the effects of application of Mibefradil to adipocytes pretreated with
Thapsigargin. Following a 30 min treatment of Thapsigargin, Mibefradil was applied for a period
of 30 min. Interestingly, the Mibefradil induced calcium increase was blocked in pretreated cells
(Fig. 9). Preincubation of 10 µM Thapsigargin for 30 min blocked the effect of increasing
intracellular calcium levels normally seen when Mibefradil was applied onto white adipocytes
(P<0.001 compared with 10µM MIB alone; Fig 9c). Higher concentrations of Mibefradil (25 µM
and 50 µM) were also tested (Figs. 10-11). At each of these concentrations, Thapsigargin
abolished the Mibefradil induced calcium increase (Fig. 9-11). Taken together, these results
suggested that Mibefradil induced calcium increase in white adipocytes was likely caused by
calcium release from the endoplasmic reticulum.

24

Figure 8. Thapsigargin (THAP) induced a calcium increase in white adipocytes. A)
Representative graph of fluorescence excitation ratio (340nm/380nm) corresponding to
intracellular calcium levels over a period of 30 min in white adipocytes treated with 10 µM
THAP.

A.
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B.

C.
Figure 9A-C. Pretreatment of Thapsigargin (10 µM THAP) blocked Mibefradil (10 µM
MIB) induced calcium increase in white adipocytes. A) Representative graph of fluorescence
excitation ratio (340nm/380nm) corresponding to intracellular calcium levels over a period of
30 min in white adipocytes treated with 10 µM Mibefradil (MIB). B) Representative graph of
fluorescence excitation ratio (340nm/380nm) corresponding to intracellular calcium levels over
time in pretreated white adipocytes with 10 µM Thapsigargin (THAP) followed by 10 µM
Mibefradil (MIB). C) Bar graph illustrates percent change of calcium levels. Thapsigargin and
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Mibefradil dissolved in DMSO. DMSO (5 min) and DMSO (8 min) showed no significant
increase in calcium levels (P>0.05). Pre-THAP (5 min) and THAP peak (8 min) showed a
significant increase in calcium levels (P < 0.001). DMSO (36min) and DMSO (46 min) showed
no significant increase in calcium levels (P >0.05). Post-THAP (36 min) and Post-MIB peak (46
min) showed no significant increase in calcium levels (P>0.05). Intracellular Ca stores were
depleted by treating cells for 30 min with a Ca/ATPase inhibitor, 10 µM THAP. Pretreatment
with 10 µM THAP abolished the MIB-induced increase in calcium levels (P<0.001 when
comparing pre-MIB calcium levels with Post MIB peak calcium levels.) Number of cells denoted
by N.

A.

B.
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C.
Figure 10A-C. Pretreatment of Thapsigargin (10 µM THAP) blocked Mibefradil (25 µM
MIB) induced calcium increase in white adipocytes. A) Representative graph of fluorescence
excitation ratio (340nm/380nm) corresponding to intracellular calcium levels over a period of
30 min in white adipocytes treated with 25 µM Mibefradil (MIB). B) Representative graph of
fluorescence excitation ratio (340nm/380nm) corresponding to intracellular calcium levels over
time in pretreated white adipocytes with 10 µM Thapsigargin (THAP) followed by 25 µM
Mibefradil (MIB). C) Bar graph illustrates percent change of calcium levels. Thapsigargin and
Mibefradil dissolved in DMSO. DMSO (5 min) and DMSO (9 min) showed no significant
increase in calcium levels (P>0.05). Pre-THAP (5 min) and THAP peak (9 min) showed a
significant increase in calcium levels (P < 0.001). DMSO (35 min 30 sec) and DMSO (44 min 30
sec) showed no significant difference (P>0.05). Post-THAP (35 min 30 sec) and Post-MIB peak
(44 min 30 sec) showed no significant increase in calcium levels (P>0.05). Intracellular Ca
stores were depleted by treating cells for 30 min with a Ca/ATPase inhibitor, 10ɥM THAP.
Pretreatment with 10 µM THAP abolished the MIB-induced increase in calcium levels (P<0.001
when comparing pre-MIB calcium levels with Post MIB peak calcium levels.) Number of cells
denoted by N.
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A.

B.
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C.
Figure 11A-C. Pretreatment of Thapsigargin (10 µM THAP) blocked Mibefradil (50 µM
MIB) induced calcium increase in white adipocytes. A) Representative graph of fluorescence
excitation ratio (340nm/380nm) corresponding to intracellular calcium levels over a period of
30 min in white adipocytes treated with 50 µM Mibefradil (MIB). B) Representative graph of
fluorescence excitation ratio (340nm/380nm) corresponding to intracellular calcium levels over
time in pretreated white adipocytes with 10 µM Thapsigargin (THAP) followed by 50ɥM
Mibefradil (MIB). C) Bar graph illustrates percent change of calcium levels. Thapsigargin and
Mibefradil dissolved in DMSO. DMSO (5 min) and DMSO (8 min 30 sec) showed no significant
increase in calcium levels (P>0.05). Pre-THAP (5 min) and THAP peak (8 min 30 sec) showed a
significant increase in calcium levels (P < 0.001). DMSO (17 min) and DMSO (34 min 30 sec)
showed no significant increase in calcium levels (P>0.05). Post-THAP (17 min) and Post-MIB
peak (34min 30 sec) showed no significant increase in calcium levels (P>0.05). Intracellular Ca
stores were depleted by treating cells for 30 min with a Ca/ATPase inhibitor, 10ɥM THAP.
Pretreatment with 10 µM THAP abolished the MIB-induced increase in calcium levels (P<0.001
when comparing pre-MIB calcium levels with Post MIB peak calcium levels.). Number of cells
denoted by N.
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Application of Mibefradil to white adipocytes results in lipid droplet fusion.
Our first experiment of treating adipocytes with Mibefradil did not only result in increased
intracellular calcium levels, but also induced smaller lipid droplets within cells to fuse to form
larger droplets. Lipid droplet fusion was evident by comparing differential interference contrast
(DIC) images of adipocytes before and after treatment (Fig. 12 A). Also, shown are images of
Fura-2 loaded adipocytes (380nm excitation) before and after lipid droplet fusion (Fig. 12B). To
investigate any dose-dependent effect of Mibefradil on lipid droplet fusion, the following
concentrations were used: 10 µM, 25 µM, 30 µM, 40 µM, and 50 µM. Each of these Mibefradil
concentrations induced fusion (Tables 2a-6a). 10 µM, 25 µM, 30 µM, 40 µM, and 50 µM
Mibefradil treatment resulted in lipid droplet fusion percentage values of 7.2 ± 2.9% (4
experiments), 34.5% (1 experiment), 45.5% (1 experiment), 16.4±8.1% (2 experiments), and
39.4±4.8% (9 experiments), respectively. Both 10 µM and 50 µM Mibefradil concentrations
based on average values showed dose dependency whereby increasing concentrations produced
an increased amount of lipid droplet fusion. Intermediate concentrations (25 µM, 30 µM, 40 µM)
did not based on average values did show dose dependency, which could be due to the low
number experiments performed with these concentrations. Only one experiment was completed
for each of the 25 µM and 30 µM Mibefradil treatment and two experiments were completed for
the 40 µM Mibefradil treatment. Therefore, dose dependency for these intermediate
concentrations cannot be determined and additional experiments utilizing these Mibefradil
concentrations need to be performed.
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A.

B.
Figure 12A-B. A) Differential interference contrast image of unstained white adipocytes
before (left) and after treatment with Mibefradil (right). Mibefradil (25 µM) treatment induced
lipid droplets to fuse (above). B) Ratiometric image of fura-2 loaded white adipocytes before
(left) and after treatment with Mibefradil (right). Mibefradil (25 µM MIB) treatment induced
lipid droplets to fuse. Some fusion events are shown by arrows. Regions of interest (ROI)
indicate areas of the cells used to measure Fura-2 fluorescence. White bar: 10 µm.
Application of Mibefradil to white adipocytes in an extracellular medium devoid of calcium
induced lipid droplet fusion.
Lipid droplet fusion was a common occurrence after treating white adipocytes with Mibefradil.
We investigated next whether the Mibefradil induced lipid droplet fusion depended on the
presence of extracellular calcium. When adipocytes were treated with Mibefradil in a zerocalcium environment lipid droplet fusion was present in adipocytes (Table 1). In a medium
containing calcium, Mibefradil (40µM) treatment resulted in 16.4±8.1% of cells (n= 2
experiments) showing lipid droplet fusion, while 49.4±12.0% of cells (n=3 experiments) showed
fusion with the same treatment in a medium without calcium. These results suggested that
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Mibefradil induced lipid droplet fusion was not inhibited by the lack of extracellular calcium.
Fusion events in zero calcium were actually numerically higher, but given the low number of
experiments and variability in results, additional experiments would have to be performed to test
whether this trend was significant.
Table 1. Lipid droplet fusion in white adipocytes treated with 40 µM Mibefradil in
normal and in zero calcium containing extracellular medium. Note that lipid droplet fusion
ranged widely between experiments. Number cells denoted by N.

Application of Mibefradil to white adipocytes pretreated with FCCP induced lipid droplet fusion.
Previous experiments had demonstrated that Mibefradil treatment of adipocytes pretreated with
an oxidative phosphorylation uncoupler, FCCP, still resulted in an increase in intracellular
calcium levels attributed to Mibefradil. To test whether FCCP pretreatment had an effect on
Mibefradil induced lipid droplet fusion, cells were pretreated with FCCP (10µM) for 30min. 30
min treatment with FCCP (10 µM) alone induced 0% lipid droplet fusion (2 experiments). The
application of Mibefradil to FCCP pretreated adipocytes induced lipid droplet fusion (Table 2).
A 40 µM Mibefradil application to FCCP pretreated cells induced fusion in 10.7±6.4% of cells
(n=2 experiments), compared to 16.4±8.1% in 40µM Mibefradil alone (n=2 experiments). At 30
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µM, Mibefradil application induced fusion in 39.1±29.3% of FCCP pretreated cells (n=2
experiments), compared to 45.5% of cells for Mibefradil alone (n=1 experiment). Clearly, FCCP
pretreatment of adipocytes did not inhibit Mibefradil induced lipid droplet fusion, but due to the
low numbers of experiments and variability in results between experiments, no statistical
analysis was warranted. A 40 µM Mibefradil treatment in pretreated adipocytes did not show a
significant difference (P<0.001) in lipid droplet fusion when compared to a Mibefradil (30 µM)
treatment alone. It would be important to increase the number of experiments in future studies to
test possible dose dependency of the effect of Mibefradil and any effect of FCCP pretreatment on
lipid droplet fusion.
Table 2. Lipid droplet fusion in white adipocytes pretreated with FCCP followed by
different Mibefradil concentrations. R1: 30 µM Mibefradil, R2: 40 µM Mibefradil. Note that
lipid droplet fusion ranged widely between experiments. Number of cells denoted by N.
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Application of Mibefradil to white adipocytes pretreated with Thapsigargin prevented lipid
droplet fusion.
As shown above, pretreatment of adipocytes with Thapsigargin inhibited Mibefradil induced
calcium increase. Next, we investigated whether Thapsigargin pretreatment would, in addition to
its effect on abolishing Mibefradil induced calcium increase, also have an effect on lipid droplet
fusion attributed to Mibefradil. White adipocytes treated only with Thapsigargin (10 µM) did
not show any lipid droplet fusion. Pretreatment with Thapsigargin followed by the application of
10µM and 25µM Mibefradil fully blocked the Mibefradil induced effects of fusion (Table 3),
whereas fusion was observed in 3 out of 7 experiments at 50µM Mibefradil, suggesting that
higher doses of Mibefradil might have overcome the effect of emptying the ER stores of calcium.
Thus, in most cases, fusion was inhibited when endoplasmic reticulum (ER) calcium stores were
emptied by Thapsigargin, suggesting that calcium release from the ER is an important factor in
causing Mibefradil induced lipid droplet fusion.
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Table 3. Lipid droplet fusion in white adipocytes pretreated with Thapsigargin followed
by different Mibefradil concentrations. R1: 10 µM Mibefradil, R2: 25 µM Mibefradil, R3: 50 µM
Mibefradil. Note that lipid droplet fusion ranges widely between experiments. Number of cells
denoted by N.

Calcium levels in white adipocytes undergoing lipid droplet fusion induced by Mibefradil vary
considerably.
The finding that Thapsigargin inhibited both Mibefradil induced calcium increase and lipid
droplet fusion suggested a possible link between calcium and lipid droplet fusion. To further
investigate the relationship between the intracellular calcium concentration and lipid droplet
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fusion, we analyzed the fusion events and correlated them to the calcium levels. Fusion of lipid
droplets was associated with a wide range of calcium levels (Fig.13). A more detailed analysis of
correlating the intracellular calcium concentration of the adipocyte as lipid droplets fused is
shown in Figure 14. Fig. 14A, shows adipocytes that fused after the concentration of calcium had
been reduced from its initial peak. In fig. 14B, fusion also did not coincide with the initial
calcium peak, but occurred at a later time point at which the calcium concentration was still
elevated close to the level of the initial calcium peak. Fig. 14C shows examples of cells in which
the calcium concentration continued to increase and fusion occurred at a time when the
concentration of calcium was higher than the calcium concentration of the 1st peak. Taken
together, adipocytes underwent lipid droplet fusion at varying intracellular calcium
concentrations. Additionally, lipid droplet fusion occurred at varying times after the first calcium
peak had been reached, suggesting that the initial rise in calcium may have triggered signaling
events that resulted in lipid fusion further downstream. The majority of lipid droplet fusion
events in white adipocytes treated with Mibefradil took place between 13-19 min (Fig. 15). Thus,
lipid droplet fusion occurred 8-14 min after Mibefradil addition.
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Figure 13. Calcium levels corresponding to lipid droplet fusion in white adipocytes
treated with 50 µM Mibefradil. This plot illustrates lipid droplet fusion occurred at varying
levels of calcium, ranging from ratios as high as 2.6 to as low as 0.5. Each dot represents a
single cell.
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Figure 14. Calcium levels of white adipocytes treated with 50 µM Mibefradil (MIB) at
three major stages: Pre-Mibefradil levels, 1st peak (Post-Mibefradil), and Fusion. A-C) Graphs
show fusion of lipid droplets within adipocytes occurred at varying calcium levels. PreMibefradil represent calcium concentration of adipocytes prior to Mibefradil treatment. The
maximum calcium levels post Mibefradil treatment is represented as 1st peak. The calcium levels
at which lipid droplets fused within adipocytes is represented by fusion. Number of cells denoted
by N.
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Figure 15. Calcium levels at time of lipid droplet fusion in white adipocytes treated with
50 µM Mibefradil. Scatter plot showing lipid droplet fusion frequently occurring between 13-19
min post treatment.
Mibefradil induced lipid droplet fusion preceded cell death in white adipocytes.
Previous experiments demonstrated that Mibefradil, in addition to causing an increase in
intracellular calcium levels and subsequent lipid droplet fusion, also resulted in the death of
some white adipocytes at various times throughout the 30-minute treatment period. Death was
accompanied by the disintegration of the plasma membrane of white adipocytes and the release
of the cells’ contents into the extracellular medium (Fig. 16). The effect of the different
concentrations of Mibefradil on cell death appeared to show dose dependency between 10 µM
and 50 µM, whereby increasing concentrations produced an increased amount of cell death
(Table 6). A 10 µM Mibefradil treatment induced on average 1.6±1.0% cell death in white
adipocytes (n=4 experiments) (Table 6). A 50 µM Mibefradil treatment induced on average
36.8±9.7% cell death (n=9 experiments). Intermediate concentrations (25 µM, 30 µM, 40 µM)
based on average values did not show dose dependency. A 25 µM Mibefradil treatment induced
on average 3.4% cell death (n= 1 experiment) (Table 6). A 30 µM Mibefradil treatment induced
on average 30.3% cell death (n=1 experiment) (Table 5). A 40 µM Mibefradil treatment induced
on average 29.9±25.7% cell death in adipocytes (2 experiment) (Table 4). However, the low
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number of experiments could be the reason for the wide range in cell deaths seen at the
intermediate concentrations. Only one experiment was completed for each of the 25 µM and 30
µM Mibefradil treatment and two experiments were completed for the 40 µM Mibefradil
treatment. While cell death was clearly higher at 50µM compared to 10µM of Mibefradil,
additional experiments utilizing intermediate Mibefradil concentrations needed to be performed
to establish a statistically significant dose dependency for the effect of Mibefradil on cell death.
Taken together, these experiments suggested that Mibefradil had a detrimental effect on the longterm viability of adipocytes. Next, we investigated whether the source of the Mibefradil induced
calcium increase would have an effect on Mibefradil induced cell death. Mibefradil induced cell
death was still present in adipocytes either deprived of extracellular calcium (Table 4) or
depleted of calcium from the mitochondrial store (Table 5). However, cell death was nearly
abolished in adipocytes deprived of intracellular calcium from the endoplasmic reticulum (Table
6). Adipocytes pretreated with Thapsigargin followed by a 10 µM Mibefradil treatment showed
0% cell death. Zero percent cell death was also seen in 25 µM Mibefradil treatment in pretreated
cells. Only 0.3±0.3% cell death was seen in pretreated adipocytes following a 50 µM Mibefradil
treatment. These results suggested that Mibefradil induced cell death could be nearly completely
blocked when the endoplasmic reticulum calcium store had been previously emptied by
Thapsigargin. The important role of the endoplasmic reticulum in enabling Mibefradil to induce
cell death merits further research to better understand the mode of Mibefradil’s action in white
adipocytes.
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Figure 16. Differential interference contrast image of unstained white adipocytes treated
with Mibefradil. Mibefradil (25 µM) treatment induced cell death in white adipocytes. Right
image shows cell membrane disintegration and diffusion of cell contents into the extracellular
medium. White arrow shows intact plasma membrane before (left) and after disintegration of
adipocytes treated with Mibefradil (right).

Table 4. Cell death in white adipocytes treated with 40 µM Mibefradil concentrations in
zero calcium and normal calcium containing extracellular medium. Note that cell death ranges
widely between experiments. Number of cells denoted by N.
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Table 5. Cell death in white adipocytes pretreated with FCCP followed by different
Mibefradil concentrations. R1: 30 µM Mibefradil, R2: 40 µM Mibefradil. Note that cell death
ranges widely between experiments. Number of cells denoted by N.
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Table 6. Cell death in white adipocytes pretreated with Thapsigargin followed by
different Mibefradil concentrations. R1: 10 µM Mibefradil, R2: 25 µM Mibefradil, R3: 50 µM
Mibefradil. Note that cell death ranges widely between experiments. Number of cells denoted by
N.
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4

CONCLUSIONS

The role of white adipose tissue in our bodies is of central interest to many researchers interested
in combating the epidemic of obesity among developed nations around the world. White adipose
tissue (WAT) is mainly located in subcutaneous regions of the abdomen and wraps around internal
organs often referred to as visceral fat. White adipose tissue functions as the storage site for fat
and in obese individuals there is an excessive amount of dietary fat (Bjorndal 2011). Normally in
WAT, fat in the form of triglycerides is broken down into fuel, or free fatty acids, for instances
when energy expenditure exceeds food intake. However, in obese individuals, there is an
abundance of free fatty acids in the blood being released by an abnormally enlarged adipose tissue
mass (Boden 2008). The excess of triglycerides, composed of free fatty acids, is stored in lipid
droplets. The study of lipid droplets in the scientific community now known as lipid droplet
biology has, through genetic techniques, focused primarily on the various proteins located on the
membrane of lipid droplets (Konige 2014). Lipid droplets are dynamic organelles that function to
store energy mainly in the form of triacylglycerol. The mobilization of these lipids is dependent
on whether the mammal is under fed or fasting conditions. Fed conditions typically accompany an
excess of calories which promote the generation and storage of triacylglycerols into the large,
unilocular lipid droplets found within white adipocytes. While at a time of fasting conditions
associated with caloric deficit the mobilization of fatty acids via regulated lipolysis of stored
triacylglycerols ensues (Brasaemle 2009; Paar 2012).
Mibefradil is a calcium channel antagonist that binds to transient low voltage activated T-type
calcium channels mainly located in vascular smooth muscle, neurosecretory cells in the brain,
kidneys, adrenal gland and pacemaker cells (Ernst and Kelly 1998). Once bound Mibefradil blocks
the influx of extracellular calcium through T-type channels and has numerous effects on these
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different tissues. Some recent studies have shown that Mibefradil is potentially capable of
preventing cancer cell proliferation and induce tumor suppression activity (Huang, Lu et al. 2015,
Gomez-Lagunas, Carrillo et al. 2016). An interesting phenomenon occurred in the process of using
Mibefradil in preliminary experiments on white adipocytes meriting future investigation.
Mibefradil induced an increase in intracellular calcium levels, unexpected for a T-type calcium
channel blocker. Additionally, it also induced lipid droplet fusion in white adipocytes.

Intracellular calcium increase in murine white adipocytes due to Mibefradil
Calcium participates in a variety of complex cellular processes, as it is a vital intracellular
secondary messenger. A critical function of this messenger is to produce calcium signals (Berridge
1997). This messenger depends on intracellular calcium stores and influx to produce these signals.
Consequently, we predicted that the mechanism by which Mibefradil caused a rise in intracellular
calcium was due either to calcium influx or calcium release from internal stores. Accordingly, the
present experiments tested whether an external medium deficient in calcium would attenuate
Mibefradil induced calcium increase. Subsequently we tested whether Thapsigargin-induced
depletion of intracellular endoplasmic reticulum calcium store as well as FCCP-induced depletion
of the mitochondrial store would prevent Mibefradil induced calcium increase.
Our first experiment aimed at confirming that Mibefradil increased cytoplasmic calcium within
white adipocytes. Mibefradil application (10-50 µM) repeatedly increased the intracellular calcium
concentration in Fura-2-loaded 3L1L cells. The next question was to determine whether
Mibefradil’s mechanism to induce calcium increase was due to calcium influx. Cells were tested
in a calcium-free medium and treated with Mibefradil. Mibefradil produced an increase in
cytosolic calcium on white adipocytes of the same magnitude than Mibefradil in regular
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extracellular medium that contained normal levels of calcium. The finding that Mibefradil still
induced an increase in calcium levels under conditions of calcium depleted extracellular
environment suggested that intracellular stores likely served as the main source of calcium.
We next investigated the source of Mibefradil induced calcium increase in cells treated with 10µM
FCCP to deplete mitochondria calcium stores. The effects of the pretreatment of white adipocytes
with FCCP did not prevent the Mibefradil induced calcium increase. Mibefradil still caused a rise
in calcium levels in white adipocytes that had been pretreated with the mitochondrial uncoupler
FCCP, indicating that this organelle is unlikely the source of the Mibefradil induced increase in
calcium in white adipocytes.
We next investigated the role of endoplasmic reticulum stores of calcium as the source of the
Mibefradil induced calcium increase. Thapsigargin irreversibly blocks the endoplasmic reticulum
Ca-ATPase pump and thereby prevents the refilling of the ER stores, resulting in calcium store
depletion. Thapsigargin (10µM) application to white adipocytes resulted in a transient increase in
intracellular calcium levels. Depletion of Thapsigargin-sensitive calcium stores did prevent the
Mibefradil induced calcium increase in white adipocytes, suggesting that the calcium source
mobilized by Mibefradil was the endoplasmic reticulum. Therefore, we propose that the direct
source of calcium after Mibefradil treatment in mouse white adipocytes is through endoplasmic
reticulum channels. Identifying the mechanism in which the blocking of T-type calcium channels
by Mibefradil resulted in calcium release from the endoplasmic reticulum requires further research.
Alternatively, Mibefradil might have acted by a mechanism other than the known inhibition of Ttype calcium channels.

Lipid droplet fusion in murine white adipocytes due to Mibefradil
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Adipose tissue is highly specialized to be the main lipid storage tissue in the body. These cells are
responsible for the management and packaging of lipid stores. Unilocular lipid droplets present in
white adipocytes are well adapted to store large amounts of lipids, and the size of its lipid droplet
takes up a large portion of the cytoplasm. The increasing size of lipid droplets is frequently seen
because of overnutrition in obese individuals. These dynamic organelles are devoted to providing
the most efficient recycling and storing of excessive and gross amounts of fatty acids. Disruptions
in these processes lead to the disabling of lipid droplets to protect against lipotoxicity (Krahmer
2013; Walther 2012). In white adipocytes, the chief event in the progression of obesity is the
evolution of lipid droplets transforming from a small lipid droplet to a large lipid droplet (WU
2014). In our study, time lapse fluorescence microscopy showed that Mibefradil treatment also
induced lipid droplet fusion in white adipocytes. Live cell imaging of murine adipocytes revealed
that pretreatment with the endoplasmic reticulum CaATPase pump inhibitor, Thapsigargin,
prevented lipid droplet fusion in addition to blocking Mibefradil induced calcium increase. These
data indicate that the release of calcium from intracellular stores is required for lipid droplet fusion
because in the presence of Thapsigargin both fusion events and calcium increase induced by
Mibefradil were blocked. To test whether the release of calcium from stores is sufficient for lipid
droplet fusion, other experiments such as the release of calcium from intracellular stores using
caged IP3 should be performed.

Cell death in murine white adipocytes due to Mibefradil
Many proteins are located on the surface of lipid droplets. These proteins are devoted towards
regulating the synthesis of lipids, enacting fusion of lipid droplets and mediating the hydrolysis of
lipids. Lipid droplet fusion has been directly linked to FSP27/CIDEC proteins. It has been
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demonstrated that the overexpression of these proteins generates larger and fewer lipid droplets
via homotypic fusion (Urritia 2015). The deviation of a controlled amount of triacylglycerol in
storage is regulated by specialized proteins on lipid droplets. However, inhibition of these
adipocyte-specific lipid droplet-associated proteins can induce lipotoxicity. An essential role of
lipid droplets is to quarantine overaccumulated lipids from entering the cytosol of adipocytes and
thereby safeguarding the adipocyte from the damaging effect of amassing excessive free fatty acids
(FFA). An elevated release of FFA from enlarged adipocytes initiates inflammation and lipolysis
in adipose tissue (Matsuda 2013). In our study, Mibefradil caused the lipid droplets to fuse into
large unilocular lipid droplets and subsequently caused the disintegration of the plasma membrane
of the adipocyte. Mibefradil induced adipocyte apoptosis and while its mode of action is presently
unclear, it is possible that the drug could be targeting surface proteins on lipid droplets and interfere
with their purpose of managing and providing the most efficient packaging of lipids.

Mibefradil as a prospective drug treatment
The work on Mibefradil’s effects on adipocytes is noteworthy because currently Mibefradil is in
the spotlight in the disciplines of cancer research and drug development. It has been found that Ttype calcium channels are highly expressed in numerous cancer cells. This includes a wide range
of cells such as ovarian, glioma, breast, leukemic, and many others (Huang 2015). The drug
Mibefradil is highly specific for T-type calcium channels and is a “potent” inhibitor of these
channels, making Mibefradil a very promising therapeutic for fighting cancer (Huang 2015).
Recently the National Cancer Institute (NCI) Adult Brain Tumor Consortium has placed
Mibefradil in a phase 1b clinical trial as an anticancer agent that can be used for tumor treatment.
The drug company Tau Therapeutics LLC has been developing Mibefradil to be a suitable drug
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for the treatment of cancer. They are introducing Mibefradil as a sequential combination treatment
with other antitumor applications to provide the maximal efficiency of targeted cancer treatment
(Krouse 2015). The unexpected effects of Mibefradil in white adipocytes described in this study
need to be considered as Mibefradil is advanced as a drug in human subjects. Changes in calcium
dynamics, such as increases in calcium levels resulting in lipid droplet fusion in response to
Mibefradil in white adipocytes require attention as they could signal previously unreported side
effects of the drug.
Adipocyte function can be altered by abnormal deviations in calcium levels. There is mounting
evidence that dysfunction of calcium homeostasis in adipose tissue is coupled to metabolic
diseases. It was reported that isolated adipocytes from obese individuals in the senescent
population have increased levels of cytosolic calcium (Byyny 1992). Elevated cytosolic calcium
levels are implicated to be a part of obesity-related diseases due to the calcium deposits
surrounding lipid droplets within hypertrophic adipocytes (Giordano 2013). In addition, it has been
found that an escalation of cytosolic calcium led to the modulation of de novo lipogenesis via
regulation of FAS expression and in turn stimulates triglyceride build-up and expands lipid
storage. FAS is part of the death- inducing signaling complex and functions to signal apoptosis
(Zemel 2000). In this study, Mibefradil’s effect of accumulating excess calcium in the cytoplasm
of white adipocytes led to compromised cells and cell death. Coupled with Mibefradil emerging
as a potential therapeutic application for the treatment of cancer, this drug can also be designed to
target hypertrophic adipocytes. Today medicines in design and development are focused on
having multi-purpose pharmacological and interventional approaches that treat more than a single
underlying disease. One such development the compound 1,25-dihydroxyvitamin D3
(1,25(OH)2D3), an active metabolite of vitamin D, which is being used as a preventive and
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therapeutic agent against both breast cancer and obesity. 1,25-dihydroxyvitamin D3 also acts as a
hormone that activates an apoptotic calcium signal that induces an increase in intracellular calcium
levels in breast cancer cells and adipocytes causing apoptosis. The study of this compound has not
only shed light on the link between obesity and breast cancer, but also discovered that the
modulation of apoptosis is a viable and effective means to attenuate the pathways in obesity and
breast cancer (Sergeey 2013).
In the world of obesity research, understanding the way Mibefradil exerts effects such as calcium
release, lipid droplet fusion, and cell death on adipocytes is crucial in unearthing its potential as a
therapeutic. Manmade drugs that in addition to their known function also indirectly activate other
unknown processes within a cell are an opportunity for scientists to design novel drugs that exploit
the cells and their natural functions in our bodies for other purposes. Mibefradil changes adipocytes
in interesting ways and further research into engineering pharmacological changes and repurposing
its function in adipocytes should be pursued.
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